Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large increase in short interest in August. As of August 14th, there was short interest totaling 89,867 shares, an increase of 59.5% from the July 30th total of 56,341 shares. Based on an average daily trading volume, of 78,742 shares, the short-interest ratio is presently 1.1 days. Approximately 1.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several brokerages recently commented on LSTA. Zacks Research raised Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. HC Wainwright lowered Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Finally, Weiss Ratings raised Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Institutional Investors Weigh In On Lisata Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LSTA. Bank of America Corp DE bought a new position in Lisata Therapeutics during the second quarter worth about $35,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Lisata Therapeutics during the 2nd quarter worth approximately $157,000. BlackRock Inc. acquired a new position in Lisata Therapeutics in the 2nd quarter worth $187,000. GSA Capital Partners LLP bought a new position in Lisata Therapeutics during the 2nd quarter worth about $321,000. Finally, Rangeley Capital LLC bought a new position in Lisata Therapeutics during the 1st quarter worth about $376,000. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Price Performance

Shares of Lisata Therapeutics stock traded down $0.01 on Wednesday, hitting $1.56. 36,488 shares of the company’s stock traded hands, compared to its average volume of 182,791. The firm’s 50-day moving average price is $2.16 and its two-hundred day moving average price is $3.36. The stock has a market capitalization of $14.09 million, a PE ratio of -0.95 and a beta of 0.94. Lisata Therapeutics has a one year low of $0.99 and a one year high of $5.07.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.